Patents by Inventor Sofia Järnum

Sofia Järnum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • REGIMEN FOR ENZYMATIC DESENSITISATION
    Publication number: 20260102475
    Abstract: The present invention relates to a conditioning regimen for a cell transplant to a sensitized subject, which is optionally of hematopoietic stem/progenitor cells (HSPC). The invention also relates to methods comprising administration of a cell transplant to a sensitized subject in accordance with the conditioning regimen, for the prevention or treatment of immune rejection of a cell transplant, for the prevention or treatment of engraftment failure or poor graft function of a cell transplant, or for the prevention or treatment of a disease or condition that is treated or prevented by a cell transplant. The invention also provides methods for determining whether a patient is sensitized and hence that the conditioning regimen should be used.
    Type: Application
    Filed: July 7, 2023
    Publication date: April 16, 2026
    Inventors: Sofia Järnum, Christian Kjellman
  • CYSTEINE PROTEASE
    Publication number: 20260028608
    Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG and in vitro generation of F(ab?)2 fragments.
    Type: Application
    Filed: October 9, 2025
    Publication date: January 29, 2026
    Applicant: Hansa Biopharma AB
    Inventors: Emma Andersson Nordahl, Christian Kjellman, Kaisa Karhumaa, Karl Markus Roupé, Robert Bockermann, Sofia Järnum
  • Cysteine protease
    Patent number: 12460194
    Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG and in vitro generation of F(ab?)2 fragments.
    Type: Grant
    Filed: May 18, 2021
    Date of Patent: November 4, 2025
    Assignee: Hansa Biopharma AB
    Inventors: Emma Andersson Nordahl, Christian Kjellman, Kaisa Karhumaa, Karl Markus Roupé, Robert Bockermann, Sofia Järnum
  • CYSTEINE PROTEASE
    Publication number: 20240360432
    Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG and in vitro generation of F(ab?)2 fragments.
    Type: Application
    Filed: May 18, 2021
    Publication date: October 31, 2024
    Inventors: Emma Andersson Nordahl, Christian Kjellman, Kaisa Karhumaa, Karl Markus Roupé, Robert Bockermann, Sofia Järnum